Vance Wilson, MD
Interventional Cardiology · Daytona Beach, FLNPI 1487614947
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $238,615 of the $299,676 with a category attached, or 79.6%. 38 manufacturers reported payments, led by Pfizer at 53.5% of the total. Reporting peaked in 2019 at $175,607 and has fallen 97.9% since, to $3,674 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $670.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$160K
- Novartis$57K
- Akcea Therapeutics, Inc.$21K
- E.r. Squibb & Sons, L.L.C.$18K
- Merck$13K
- Regeneron$12K
- plus $18K from 32 others
Across 80 payments — averaging $5583.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$218K
- Janssen Research & Development, LLC$194K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
- Kowa Research Institute, Inc.$10K
- AstraZeneca$9K
- Boehringer Ingelheim International GmbH$7K
What the payments were for
- Consulting fees$16,7166%
- Speaking & faculty fees$238,61580%
- Travel & lodging$36,13912%
- Food & beverage$8,1633%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 182 | $160,284 |
| Novartis | 55 | $57,298 |
| Akcea Therapeutics, Inc. | 25 | $20,600 |
| E.r. Squibb & Sons, L.L.C. | 37 | $18,496 |
| Merck | 26 | $13,124 |
| Regeneron | 11 | $11,577 |
| AstraZeneca | 16 | $6,519 |
| Boston Scientific | 12 | $6,402 |
| Medtronic | 20 | $3,787 |
| Alnylam Pharmaceuticals Inc. | 4 | $187 |
| Abbott | 7 | $172 |
| Abiomed | 2 | $134 |
| Celonova Biosciences, Inc. | 1 | $100 |
| Boehringer Ingelheim | 4 | $93 |
| Innovation Technologies Inc | 1 | $92 |
| Amarin Pharma, Inc. | 3 | $73 |
| Irhythm Technologies, Inc. | 3 | $61 |
| Esperion Therapeutics, Inc. | 4 | $61 |
| United Therapeutics Corporation | 2 | $57 |
| Amgen | 3 | $46 |
| Cvrx, Inc. | 2 | $42 |
| Impulse Dynamics (USA) Inc. | 2 | $42 |
| Kestra Medical Technology Services, Inc. | 2 | $40 |
| Novo Nordisk | 3 | $38 |
| Bardy Diagnostics, Inc. | 3 | $38 |
| Tactile Systems Technology Inc | 2 | $37 |
| Johnson & Johnson | 2 | $32 |
| Bracco Diagnostics Inc. | 1 | $30 |
| Heartflow, Inc. | 1 | $29 |
| Lexicon Pharmaceuticals, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Atricure, Inc. | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $24 |
| Philips North America LLC | 1 | $19 |
| Bayer | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $15 |
| Beckman Coulter, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$299,676 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 733 | $818,911 |
| EntrestoSacubitril/Valsartan | 187 | $231,672 |
| Repatha SureclickEvolocumab | 170 | $190,196 |
| FarxigaDapagliflozin Propanediol | 95 | $103,279 |
| JardianceEmpagliflozin | 43 | $61,536 |
| Praluent PenAlirocumab | 75 | $58,599 |
| XareltoRivaroxaban | 19 | $30,618 |
| VascepaIcosapent Ethyl | 15 | $17,009 |
| Ezetimibe | 524 | $15,239 |
| Atorvastatin Calcium | 667 | $8,926 |
| Repatha SyringeEvolocumab | 13 | $7,331 |
| Rosuvastatin Calcium | 454 | $7,226 |
| Metoprolol Succinate | 518 | $7,113 |
| Nebivolol Hcl | 120 | $6,163 |
| BrilintaTicagrelor | 11 | $5,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $160,284 | $818,911733 claims |
| NovartisEntresto | $57,298 | $231,672187 claims |
| AstraZenecaFarxiga, Brilinta | $6,519 | $108,607106 claims |
| Boehringer IngelheimJardiance | $93 | $61,53643 claims |
| Johnson & JohnsonXarelto | $32 | $30,61819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Daytona Beach
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.